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Abstract
Objectives: This study was designed to assess the dose-response relationship between tissue, blood, vaginal and rectal
compartment concentrations of tenofovir (TFV) and tenofovir diphosphate (TFVdp) and ex vivo rectal HIV suppression
following oral tenofovir disoproxil fumarate (TDF) and rectal administration of TFV 1% vaginally-formulated gel.
Design: Phase 1, randomized, two-site (US), double-blind, placebo-controlled study of sexually-abstinent males and females.
Methods: Eighteen participants received a single 300 mg exposure of oral TDF and were then randomized 2:1 to receive a
single then seven-daily rectal exposures of TFV 1% gel (40 mg TFV per 4 ml gel application) or hydroxyethyl-cellulose (HEC)
placebo gel. Blood and rectal biopsies were collected for pharmacokinetic TDF and TFVdp analyses and ex vivo HIV-1
challenge.
Results: There was a significant fit for the TFVdp dose-response model for rectal tissue (p= 0.0004), CD4+MMC (p,0.0001),
CD42MMC (p,0.0001), and TotalMMC (p,0.0001) compartments with r
2 ranging 0.36–0.64. Higher concentrations of TFVdp
corresponded with lower p24, consistent with drug-mediated virus suppression. The single oral treatment failed to provide
adequate compartment drug exposure to reach the EC50 of rectal tissue TFVdp predicted to be necessary to suppress HIV in
rectal tissue. The EC50 for CD4
+
MMC was within the single topical treatment range, providing evidence that a 1% topical,
vaginally-formulated TFV gel provided in-vivo doses predicted to provide for 50% efficacy in the ex vivo assay. The 7-daily
topical TFV gel treatment provided TFVdp concentrations that reached EC90 biopsy efficacy for CD4
2
MMC, CD4
+
MMC and
TotalMMC compartments.
Conclusion: The TFVdp MMC compartment (CD4+, CD42 and Total) provided the best surrogate for biopsy infectibility and
the 7-daily topical TFV gel treatment provided the strongest PK profile for HIV suppression.
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Introduction
Ex vivo infection of rectal and cervical biopsies has been used as
a potential biomarker of microbicide efficacy in humans. Ex vivo
tissue biopsies are infected with HIV, following either ex vivo [1–
5] or, more recently, in vivo [6,7] exposure to a topical
microbicide product. When HIV suppression in the biopsy
infectibility assay correlates with drug concentration in tissue it is
possible to derive tissue drug concentrations predicting 50–95%
suppression of ex vivo infections [8]. In the currently reported
RMP-02/MTN-006 Phase 1 rectal microbicide trial of topical and
oral TFV, drug concentrations were quantified in multiple
compartments (blood, rectal tissue, rectal/vaginal fluid compart-
ment concentrations; ‘CC’) and correlated with HIV suppression
in the ex vivo infectibility rectal tissue assay to provide a measure
of drug efficacy.
In the first rectal microbicide trial to correlate ex vivo tissue
infectibility with tissue drug concentration following in vivo
application of a product (0.1 or 0.25% UC781 gel [8]), logistic
regression was used to calculate the EC50,90,95 tissue concentra-
tions predicted to result in 50, 90 or 95% biopsy non-infectibility.
In this analysis model, it was shown that defining a tissue sample as
either infected or non-infected enabled a predictive dose-response
relationship to be identified. Tissue infection was indicated when
HIV replication in the ex vivo assay was greater than 500 pg/mL
cumulative p24 on Day 14. Although there is currently no
consensus on the optimal method for p24 quantification in the
ex vivo challenge assay, cumulative p24 on Day 14 has been found
to be a relatively reliable and precise method for quantifying rectal
ex vivo HIV replication [6–8].
The RMP-02/MTN-006 clinical trial evaluated the safety
(primary outcome), acceptability, pharmacokinetic (PK; secondary
outcome), pharmacodynamic profile (PD; exploratory outcome)
and a limited PK:PD analysis of tissue TFVdp and biopsy p24 ([6])
of TVF 1% gel (single and 7-daily exposures) and oral tenofovir
disoproxil fumarate (TDF; 300 mg; single exposure). Single oral
and topical exposures provided the opportunity to assess within-
subject comparisons of safety, PK and PD following single product
exposure. Safety, PK and PD assessment was also conducted after
7 doses of topical TFV gel, a period approaching the time needed
to reach steady state levels of TFV. The objective of this analysis
was to report on the RMP-02/MTN-006 [6] multi-compartment
correlations between PK (i.e. TFV) and tenofovir diphosphate
(TFVdp) compartment drug concentrations and PD activity (i.e.
biopsy infectibility reflected by the degree of ex vivo p24
suppression in tissue biopsies).
Methods
Study participants
Study participants (N=18; Figure 1) were healthy HIV-1
seronegative males and females with a history of consensual
receptive anal intercourse (RAI), willing to abstain from vaginal
and anal sex during active protocol phases (V2–V14, Figure 2).
Female participants were required to use an acceptable form of
contraception.
Ethics statement
The trial was IRB-approved at each site (UCLA, Los Angeles,
CA; University of Pittsburgh, Pittsburgh, PA); all participants
provided written informed consent. RMP-02/MTN-006 is regis-
tered at ClinicalTrials.gov (#NCT00984971) and is in compliance
with the CONSORT 2010 trial reporting recommendations
(www.consortstatement.org). The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Study design
The design of RMP-02/MTN-006 Phase 1 trial has been
described [6] and is briefly outlined here. This was a double-blind,
randomized, placebo-controlled comparison of oral TDF
(300 mg), rectally-applied TFV 1% gel (each dose of gel contained
40 mg of TFV), and the HEC placebo gel. Randomization was
carried out by the study pharmacist and was a two-part process.
Following enrollment, participants were randomized (2:1) to
receive TFV 1% gel (N= 12) or HEC placebo gel (N= 6). A
separate randomization was used to assign subjects, for safety
reasons, into one of two post-exposure biopsy sampling arms (A or
B) after each single exposure stage. Group A subjects were
biopsied on Days 1–3 and 7–9 and Group B subjects were biopsied
on Days 4–6 and 10–12. Each two week period of biopsy sampling
was followed by a two week washout period between stages (‘rest’;
Figure 2). At visit 3 (V3 N=18; Figure 2), all participants received
a single oral dose of TDF administered by a clinical team; this was
followed 4-weeks later (V7) by a single dose of rectally applied
product administered by the clinical team. Four weeks later,
participants received seven sequential daily doses of their assigned
products; six of which were self-administered each morning with
the 7th rectal dose administered in the clinic by the clinical team
(V12; Figure 2). Rectal biopsy infectibility assays were repeatedly
performed over 2 weeks following each treatment phase, with
concurrent CC (i.e. compartment concentrations) measurements
of: (i) TFV from rectal and vaginal fluids, blood and rectal tissue
and; (ii) TFVdp from total peripheral blood mononuclear cells
(TotalPBMC), CD4+ lymphocytes from PBMC (CD4+PBMC),
CD42 lymphocytes from PBMC (CD42PBMC)] and tissue [whole
tissue biopsy, total isolated mucosal mononuclear cells (TotalMMC),
CD4+ lymphocytes from MMC (CD4+MMC), CD42 lymphocytes
from MMC (CD42MMC)]. CC and explant tissue samples were
taken at time points from 30 minutes through 14 days following
each single exposure (oral and topical) and at 30 minutes following
the 7-day exposure. Biopsy infectibility and compartmental PK
measures were obtained at 7 timepoints following each product
exposure (from 30 minutes to 12 days; e.g., V3, 5, 6, 7, 9, 10 and
12, ‘*’; Figure 2). These paired (blood/biopsy) timepoints were
included in this dose-response analysis. CC and biopsy samples
taken from all participants at baseline (V2; no drug exposure) as
well as from those participants randomized to the placebo arm
(N=6; V7, 9, 10 and 12) did not follow drug exposure and so were
not included in the dose-response analysis. Sample size (n = 18)
was based on similar phase 1 studies of topical microbicides [7].
Enrollment began November 2009 and was completed July 2010.
Baseline demographic and clinical characteristics for each group
are reported in the original trial paper [6].
Study products
300 mg tablets of TDF were supplied by Gilead Sciences Inc.
(Foster City, CA). TFV 1% gel providing 40 mg TFV per 4 mL
application, and HEC gel were supplied by CONRAD (Arlington,
VA). The vaginal formulation of TFV 1% gel used was pH
adjusted to 4–5 with an osmolarity of 3111 mOsmol/kg and the
HEC placebo was isotonic with a pH of 4.4, osmolarity of 304
mOsmol/kg [6] and a viscosity similar to other microbicide gel
candidates [9]. TFV and HEC gels were pre-filled into single-use,
opaque applicators (HTI Plastics; Lincoln, NE) containing
approximately 4 mL of gel.
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PK analyses
Plasma TFV and tissue TFVdp concentrations were determined
by previously described LC-MS/MS methods validated for all
matrices at The Johns Hopkins Clinical Pharmacology Analytical
Laboratory and met FDA bioanalytical validation criteria [10].
TFV concentrations were determined in both peripheral blood
mononuclear cells (PBMC) and mucosal mononuclear cells
(MMC) for rectal and vaginal fluids (ng/sponge; Ultracell Aspen,
Caledonia MI) in addition to plasma (ng/mL) and tissue (ng/mg)
concentrations. TFVdp concentrations were also determined for
TotalPBMC, CD4
+
PBMC, CD4
2
PBMC, TotalMMC, CD4
+
MMC,
CD42MMC and Tissue. CD4
+ and CD42 subsets from both
PBMC and MMC were acquired by MACS Miltenyi Biotec
QuadroMACS separation unit (Miltenyi Biotec Inc., Auburn,
CA). The measured value from each PK assay was used unless the
PK value was determined to be between the lower limit of
quantification (LLOQ) and the lower limit of detection (LLOD).
In these cases, a number equal to half that assay’s LLOQ was
imputed for that PK value.
PD analyses
At baseline (V2) and timepoints following product exposure (V3,
5, 6, 7, 9, 10 and 12; Figure 2), endoscopic biopsies were collected
in 50 mL RPMI (with 1.125 mg/mL of Fungizone and 50 mg/mL
of Zosyn) and transported to the laboratory for ex vivo infection
within ,1–2 hours using a common viral stock of HIV-1BaL (104
TCID50), as previously described [1,11,12]. Supernatants for p24
quantification were collected every three days during each 14-day
infectibility assay (Days 1, 4, 7, 11 & 14). Results were averaged
across quadruplicate assays and reported as cumulative p24 (p24
HIV antigen ELISA; NCI, Bethesda, MD) where the assay’s
LLOQ was 10 p24 pg/mL. Non-detectable cumulative p24
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0111507.g001
Figure 2. Study flow diagram. Paired measures from compartment concentrations (CC) and both CC and biopsy samples (*) taken at the bolded
visits: V3 (Visit 3: ,30 mins post single oral dose), V5 (1–6 days post V3 dose), V6 (7–9 days post V3 dose), V7 (,30 mins post single topical dose), V9
(1–3 days post V7 dose), V10 (7–12 days post V7 does) and V12 (,30 mins post 7th daily dose) used in the dose-response analysis.
doi:10.1371/journal.pone.0111507.g002
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measures at Day 14 were converted to 1/2 the LLOQ prior to log
transformation. Cumulative p24 was used here to provide both a
continuous (i.e. pg/mL) and binary (,500 pg/mL cumulative
p24= ‘non-infected’; $500 p24 pg/mL= ‘infected’) measure of
virus growth [8,13].
Statistical analysis
TFV measures from four compartments (rectal fluid, vaginal
fluid, plasma, and rectal tissue) and TFVdp measures from seven
compartments (TotalPBMC, CD4
+
PBMC, CD4
2
PBMC, TotalMMC,
CD4+MMC, CD4
2
MMC, and rectal tissue) were log10 transformed
and paired with the corresponding log transformed explant
infectibility result (i.e. log10 cumulative p24 at Day 14) for each
subject and sampling time. The number of CC and p24 paired
measurements (N= 18) are reported in Table 1. Paired CC and
p24 endpoints were entered into a three parameter, log-log, Hill
slope, non-linear model (1) where the fit of the model was tested by
nonlinear least-squares ANOVA and the proportion of variance
that each model explained (r2) was calculated [i.e. (12) the sum of
the squared distances from each fitted curved divided by the
squared distances from a horizontal line].
Log10(p24)~bz(a{b)=(1z10
((LogDose){c)) ð1Þ
The fit of each three-parameter non-linear model was compared
to an alternative four parameter model using the information
criterion of Akaike (AIC), where a lower AIC indicates improved
model fit [14].
The ability of a microbicide treatment to suppress p24 in the ex-
vivo assay is an indication of treatment efficacy, where lower
concentrations of p24 indicate virus suppression. Based on earlier
published methodology [8], biopsy assays resulting in a cumulative
p24 below 500 pg/mL were categorized as ‘suppressed’ and biopsy
assays with a cumulative p24 at or above 500 pg/mL were ‘not-
suppressed.’ This binary categorization of ex-vivo endpoints (i.e.
‘suppressed’ or ‘not suppressed’) was then used in a logistic
regression model of the relationship between probability of ex vivo
HIV suppression and CCs. CCs necessary to suppress 50, 90 and
95% of biopsy HIV (i.e. EC50, EC90, and EC95) were calculated by
interpolation of the logistic curve at 0.50, 0.90 and 0.95
probability. A predicted EC50, EC90, or EC95 CC that fell within
the PK range (min-max) found following each treatment [15] was
evidence that the treatment provided a CC with the potential to
meet EC50,90,95 levels of efficacy.
All statistical analyses were performed using SAS/STAT
software Version 9.3 of the SAS system for Windows (SAS
Institute Inc., Cary, NC) and an alpha= 0.05.
Results
Paired CC and p24 data meeting the following criteria were
included in the analysis: (i) collected post active drug, (ii) at
timepoints with concurrent ex vivo infectibility assays and, (iii)
with measurable CC and p24 concentrations. For example, of the
102 possible rectal fluid TFV and p24 paired measurements
following the single oral (N= 18 receiving active drug), single
topical (N= 12) and 7-daily topical exposure stages, there were,
respectively, 38, 27 and 12 HIV ex vivo p24 measures that were
paired with detectable rectal fluid TFV CCs (‘TFV Rectal Fluid;
Table 1; see File S1 for non-detectable and missing data
frequencies). There were no detectable CC measures of TFVdp
from either TotalPBMC or CD4
+
PBMC at the time-points when
biopsies were acquired (‘*’, Figure 2); no further analyses were
performed on these compartments.
Compartment drug-HIV suppression correlations
The non-linear model fit was improved (smaller AIC) for the
three parameter, compared to the four parameter, regression
model that was used to correlate TFV and TFVdp CCs with tissue
infectibility (cumulative p24; Table 2).
TFVdp: There was a significant fit by non-linear least squares
analysis of variance, for the TFVdp dose-response model for rectal
tissue (p=0.0004; Figure 3a.), CD4+MMC (p,0.0001; Figure 3b.),
CD42MMC (p,0.0001; Figure 3c.), TotalMMC (p,0.0001; Fig-
ure 3d.) compartments with r2 ranging 0.36–0.64. Higher
concentrations of TFVdp corresponded with lower p24, consistent
with drug mediated virus suppression. Non-linear curves provided
a clear upper asymptote, where lower ranges of drug were
ineffective in suppressing virus growth (Figures 3a–d). There was
little or no evidence of a lower asymptote, where suppression of
HIV reached the lower limit of p24 quantification and additional
drug was not increasingly efficacious (Figure 3a–d). No significant
CC:p24 relationships were identified in the blood-derived samples
of CD42 PBMC (Table 2) at the PK timepoints that were
concurrent with an endoscopic biopsy procedure.
Table 1. Number of detectable, concurrent, paired CC and p24 measurements following each treatment.
Compartment Single Oral* Single Topical** 7-Daily Topical*** Total
TFV Rectal Fluid 38 27 12 77
TFV Vaginal Fluid 6 1 2 9
TFV Plasma 45 16 12 73
TFV Rectal Tissue 14 10 10 34
TFVdp Rectal Tissue 10 17 12 39
TFVdp CD42MMC 17 17 11 45
TFVdp CD4+MMC 10 13 9 32
TFVdp TotalMMC 4 14 9 27
TFVdp CD42PBMC 9 1 0 10
*Post Single Oral (V3, 5 & 6). Maximum of 18 (N; number of subjects)63 (V; visits) = 54 paired CC:p24 measurements, 12 for vaginal fluid [4 (f; female subjects)63 (V)].
**Post Single Topical (V7, 9 &10). Maximum of 12 (N)63 (V) = 36 paired CC:p24 measurements,6 for vaginal fluid [2(f)63 (V)].
***Post 7-Daily Topical (V12). Maximum of 12 (N)61 (V) = 12 paired CC:p24 measurements, 2 for vaginal fluid [2(f)61 (V)].
doi:10.1371/journal.pone.0111507.t001
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TFV: There was a significant fit for the non-linear model of
rectal fluid TFV and p24 biopsy suppression (Figure 3e;
p=0.0012); higher concentrations of TFV correlated with lower
cumulative p24. Although statistically significant, this rectal fluid
TFV CC:p24 suppression model had a relatively low r2 value
(0.17). This is likely reflective of many high CC values [,4–6
log10(TFV) ng/sponge] not associated with suppression of biopsy
p24 [,3–4 log10(p24) pg/mL; Figure 3e]. No significant CC:p24
relationships were identified for TFV in vaginal fluid, plasma or
rectal tissue, the latter in contrast to the significant relationship
found for TFV in rectal fluid (Table 2).
TFVdp and TFV EC50,90,95
Logistic regression analyses were performed for those TFV and
TFVdp compartments showing significant dose-response relation-
ships: TFVdp concentrations in rectal tissue, CD4+MMC,
CD42MMC, TotalMMC and TFV concentrations in rectal fluid
(Figure 3a–e). The concentrations of drug (TFV or TFVdp) in
each compartment predicted to suppress biopsy HIV below a
cumulative p24 of 500 pg/mL were determined using a logistic
regression model. The fit of the logistic regression model was
measured by the area under the receiver operator characteristic
curve (‘AUC’) where an AUC=1.0 indicates perfect prediction of
biopsy suppression [16]. The fit of the logistic models ranged from
0.83–1.00 AUC. Interpolation at the 50, 90 and 95% HIV
suppression probability levels of the logistic curve provided
EC50,90,95 point estimates for TFV and TFVdp CCs (Table 3).
Bootstrap samples (x1000, data not shown) were run and results
were highly consistent at the EC50 endpoint (within 4% of the
Table 3 EC50 values) but less consistent at the EC90 and EC95
efficacy levels presumably due to few observations at those
modeled concentrations.
The likelihood that a treatment (i.e. single oral TDF, single
topical TFV gel or 7-daily topical TFV gel) would provide a CC
necessary for ex vivo HIV suppression (i.e. EC50,90,95) was
evaluated by determining whether the EC50,90,95 point estimates
were within the range found following each treatment ([15];
Table 2). An EC50,90 and/or EC95 estimate that fell within the
likely range found in subjects following a treatment provided
evidence that the treatment had the potential to suppress biopsy
HIV growth at the 50, 90, or 95% probability level. Conversely, if
the range in actual CC following a treatment was less than the
predicted EC50,90,95 levels then the treatment failed to provide CC
at levels predicted to be necessary for suppression of HIV growth
in the biopsy assay.
The single oral treatment failed to provide adequate CC to
reach the EC50 levels of rectal tissue TFVdp predicted to be
necessary to suppress HIV in the rectal biopsy [ie. TFVdp (fmol/
mg) = 1660; Table 3] at 24 hours post treatment (i.e. TFVdp
C24 hrs (fmol/mg) =BLQ-991; min-max; [15]). The EC50 level for
CD4+MMC (2884 fmol/10
6 cells; Table 3) was within the single
topical treatment range at C30 min (BLQ-3950 fmol/10
6 cells;
[15]), providing evidence that a TFV 1% gel could deliver a
CD4+MMC concentration necessary for 50% efficacy in the ex vivo
assay. The 7-daily topical TFV gel treatment provided TFVdp
concentrations (min-max) that reached EC90 biopsy efficacy for
CD42MMC (C30 min =BLQ-12000 fmol/10
6 cells; Table 2 [15];
EC90 = 1318 fmol/10
6 cells Table 3), CD4+MMC (C30 min =BLQ-
31200 fmol/106 cells [15]; EC90 = 13183 fmol/10
6 cells Table 3)
and TotalMMC (C30 min =BLQ-13900 fmol/10
6 cells [15];
EC90 = 8318 fmol/10
6 cells Table 3) compartments. The
EC50,90,95 serve as point estimates of efficacy where the range in
in vivo drug concentrations found following use of an efficacious
product would, ideally, be higher than the EC50,90,959s found in
this ex vivo model. Up to a 4-log spread in compartment drug
concentration was found following the single oral, single rectal and
7 day rectal dosing, where only a small proportion of subject
timepoints resulted in concentrations exceeding the predicted
EC90 doses. For example, only 3/12 of detectable CD4
2
MMC
concentrations of TFVdp were above the EC90 of 1318 fmol/10
6
cells (Figure 3c), providing evidence suggestive of at least partial
efficacy in this model.
Discussion
This Phase 1 trial confirmed that the ex vivo biopsy challenge
model can provide a pharmacodynamic endpoint (p24 suppres-
sion) correlated with in vivo drug concentrations and varied by
treatment regimen. The pharmacodynamic endpoint of p24
suppression following HIV-1BaL infection of freshly-acquired
Table 2. TFV and TFVdp dose, p24 suppression response non-linear models.
Compartment n p r2 AIC* (3-param1) AIC (4-param11)
TFV Rectal Fluid (ng/sponge) 77 0.0012 0.17 149.29 151.29
TFV Vaginal Fluid (ng/sponge) 9 ns 0.26 27.83 29.83
TFV Plasma (ng/mL) 73 ns 0.01 155.84 157.84
TFV Rectal Tissue (ng/mg) 34 ns 0.13 81.41 83.41
TFVdp Rectal Tissue (fmol/mg) 39 0.0004 0.36 81.96 83.96
TFVdp CD42MMC (fmol/10
6 cells) 45 ,0.0001 0.64 69.42 71.42
TFVdp CD4+MMC (fmol/10
6 cells) 32 ,0.0001 0.53 63.57 65.57
TFVdp TotalMMC (fmol/10
6 cells) 27 ,0.0001 0.57 55.55 57.55
TFVdp CD42PBMC (fmol/10
6 cells) 10 ns 0.46 14.84 16.84
p=probability of non-linear model fit.
ns = non-significant at alpha 0.05.
n = number of CC:p24 paired measurements.
r2= (1-) the sum of the squared distances from each fitted curved divided by the squared distances from a horizontal line.
*AIC =Akaike information criterion value. The 3-parameter non-linear model provided lower AIC values indicating a better fit than an alternative 4-parameter model.
13-parameter model: Log10(p24)~bz(a{b)=(1z10
((LogDose){c)):
114-parameter model: Log10(p24)~bz(a{b)=(1z10
(((LogDose){c){d)):
doi:10.1371/journal.pone.0111507.t002
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human tissue biopsies has yet to be validated as a bio-indicator of
HIV prevention in a large scale human efficacy trial but does
present the closest surrogate currently available. This paper
demonstrated that tissue HIV infectibility (cumulative p24) was
inversely correlated with in vivo concentrations of both TFV and
TFVdp. Statistically significant, non-linear dose-response relation-
ships with reduced tissue infectibility were found for one TFV
compartment and four TFVdp compartments; the dose-response
relationships were highly significant for TFVdp in whole rectal
tissue, CD4+MMC, CD4
2
MMC and TotalMMC compartments. The
finding that TFVdp, the active metabolite of TFV, was more
predictive of ex vivo virus inhibition than TFV demonstrates the
utility of measuring TFVdp in cellular spaces. Isolation of cells for
the measurement of TFVdp may not be necessary as TFVdp in
whole rectal tissue was found to be as predictive of a
pharmacologic response as TFVdp in isolated cell populations.
Figure 3. Tenofovir (TFV) and Tenofovir Diphosphate (TFVdp) concentration and biopsy cumulative p24 dose-response
relationships. Results are shown for those CC:p24 paired measurements with detectable concentrations of drug following single oral TDF ( ),
single topical TFV gel (%) and 7-day topical TFV gel (.) microbicide treatments for the dose-response relationship between CC drug concentrations
and ex vivo p24 levels. Figure panels A-D show TFVdp in (A) rectal tissue, (B) TFVdp CD4+MMC, (C) TFVdp CD4
2
MMC, (D) TFVdp TotalMMC and (E)
Tenofovir (TFV) rectal fluid concentration. Parameters from the log-log non-linear model with a Hill slope factor of –1.0, where r2 and probability
levels for the fit of the non-linear least-squares analysis of variance are embedded. Vertical lines indicate the EC50 and EC90 calculated by the logistic
regression analysis as the compartmental drug concentrations predicted to provide 50 and 90% efficacy in the explant infectivity assay.
doi:10.1371/journal.pone.0111507.g003
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These findings support the measurement of TFVdp from whole
tissue homogenates in clinical trials, as isolation of cells from tissue
may not be necessary to obtain a measure of TFVdp that is related
to activity. The ability to describe a concentration-response
relationship allowed identification of target concentrations of
TFVdp in specific compartments so providing a means to ensure
that different dosing strategies result in adequate in vivo TFVdp
ranges for ex vivo HIV inhibition.
Robust dose-response correlates predicting the in vivo CCs in
tissue, blood, rectal/vaginal fluid compartments needed for ex vivo
suppression of HIV (i.e. EC50,90,95) were found using logistic
regression analyses. In demonstrating these correlations, this
intensive Phase 1 trial design, involving the measurement of
multiple PK endpoints in multiple tissue/fluid compartments and
the PD ex vivo assay endpoint, predicted CCs necessary for
ex vivo suppression and, by inference, in vivo dosing. The ex vivo
biopsy assay for HIV infectibility uses intact, freshly-acquired,
tissue samples, providing one of the closest pre-clinical surrogates
to a human efficacy clinical trial. Phase 1 rectal microbicide study
designs that integrate safety, acceptability, and PK/PD measure-
ments have the potential to provide early indications of harm and/
or potential efficacy of candidate products prior to embarking on
larger, longer and more expensive Phase 2B/3 trials.
When drug concentrations are independently varied, correla-
tions between dose, in vivo drug concentration and infectibility
can be used to predict the drug concentration needed to effectively
suppress HIV infection, ex vivo [8]. The single doses of oral and
topical drugs used here did not allow for correlations to be made
with initial doses but a wide range in in vivo drug concentrations
were found following the various treatment regimens tested. The
in vivo drug concentrations following the 7-daily topical TFV gel
treatment were quantifiable at the EC90 level in various
compartments, and were within the range found 30 minutes post
product use. The single oral TDF dose did not provide a high
enough in vivo drug concentration for even a 50% probability of
ex vivo suppression. The single topical TFV gel treatment
provided evidence of partial suppression in some compartments
but did not reach the 95% probability of suppression in any of the
compartments tested.
The statistical methodology used here, and in the previous
UC781 biopsy challenge trial [8], can inform on the design of
future trials to reduce the number of biopsy samples required,
increase power and provide relevant information from these small,
early stage clinical studies. Placebo and baseline infectibility data
are generally associated with high p24 variability and low
statistical power [8]. Baseline and placebo data were not used
(nor needed) here as the intent was to study the compartmental
concentration-response relationship only following active dose(s) of
the drug. Although the dose-response models found were
consistent with drug-mediated virus suppression, there was only
the merest indication of a lower asymptote, where suppression of
HIV reached the lower limit of p24 quantification and increased
drug would lead to diminished effect. Dose-ranging biopsy
challenge studies are needed to provide a range of drug mediated
HIV suppression in order to populate both upper and lower
asymptotes of the dose-response curve. A clearly defined lower
asymptote, where tissue/blood drug concentrations were correlat-
ed with p24 suppression in the explant assay, following in vivo
exposure to a product, would provide the range of in vivo drug
that would reliably suppress HIV in this model. Ideally, this range
that would be representative of the range in in vivo compartmen-
tal drug concentrations found amongst users of the product.
The dose-response relationships reported here are specific to the
TDF 300 mg tablet, the TFV 1% gel study product and the dosing
regimens used. The EC50,90,95 levels calculated cannot be easily
extrapolated to other doses, drugs and treatment regimens but do
provide an efficacy endpoint, expressed in units of in vivo PK
parameters, that could be comparable between studies. In the
CHARM-01 study (ClinicalTrials.gov: NCT01575405) the corre-
lations found in the RMP-02/MTN-006 study described in this
paper will be reassessed for three different formulations of TFV
1% gel to evaluate whether re-formulation impacts the clear dose-
response relationships found with the formulation of TFV 1% gel
used in the RMP-02/MTN-006 study. For example, while
compartment concentrations of TFVdp in CD4+ PBMC and
CD4Total were non-detectable at the time points where blood
levels were paired with p24 biopsy measurements (the only time
points reported here), there were detectable blood levels at
sampling periods post exposure that were not paired with biopsy
sampling. These are reported in our concurrently submitted
manuscript comparing timing of drug detection in multiple
compartments from the same Phase 1 trial [15]. Although these
derivations apply only to TFV and the particular formulations and
delivery methods tested, the analytical framework can be applied
to many promising candidate microbicides.
The high titer of HIV infection used here (HIV1BaL; 10
4
TCID50), far in excess of the titer found in semen [17], was
previously found to reduce inter- and intra- subject variability in
this tissue assay compared to a lower 102 TCID50 titer [8]. The
risk of transmission during anal intercourse has been estimated at
Table 3. Compartment TFV and TFVdp efficacy concentrations (EC50,90,95) predicted by logistic regression to suppress HIV
infection following single oral TDF, single topical TFV 1% gel and 7-day topical TFV 1% gel in vivo product use.
Compartment (measured unit) Predicted Efficacy
1
EC50 EC90 EC95
TFV Rectal Fluid (ng/sponge) 4.96106 3.661010 3.461011
TFVdp CD42MMC (fmol/10
6 cells) 661 1318 1549
TFVdp CD4+MMC (fmol/10
6 cells) 2884 13183 19498
TFVdp TotalMMC (fmol/10
6 cells) 2138 8318 12023
TFVdp Rectal Tissue (fmol/mg) 1660 10233 16596
1Predicted compartment dose concentrations to suppress 50, 90 and 95% of HIV infection interpolated from the logistic regression probability curve where infection
was defined as cumulative p24 pg/mL $500.
Actual drug concentrations in the delivered product were 300 mg tenofovir disoproxil fumarate in the oral pill (equivalent to 245 mg of tenofovir disoproxil) and
40 mg/4 mL tenofovir in each topical gel application.
doi:10.1371/journal.pone.0111507.t003
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0.65–1.7% [17], so perhaps it is not surprising that the use of
higher titer inoculants than those found in vivo result in higher
infectibility rates ex vivo (,60% of explants HIV1BaL102 TCID50
[7]) in this model system. Drug treatments that reliably suppress
such high HIV titers ex vivo set a high bar for drug mediated
efficacy assays, and may overestimate the drug dose needed
in vivo to prevent acquisition of HIV infection. The choice of
isolate could increase the power of these analysis methods if a
primary or mucosal-derived virus isolate was found to reliably
infect mucosal tissue at lower, more virologically relevant
infectious titers. Dose-ranging, use of sampling time points that
reflect the known pharmacokinetic profile in each compartment,
and use of more virulent HIV isolates may provide more reliable
and valid dose-response analytics and derived results.
In summary, the TFVdp MMC compartment (CD4+, CD42
and Total) provided the best surrogates for biopsy infectibility and
the 7-daily topical TFV gel treatment provided the strongest PK
profile for HIV suppression. Although the sample size here was
relatively small (N= 18, where only N= 12 received the microbi-
cide gel formulation), the dose-response models reached statistical
significance showing that meaningful, informative findings can
result from this type of small, intensive PK/PD study.
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